Fulgent Genetics Inc Stock News

Once again, the company exceeded quarterly expectations on the flare-up of another pandemic wave.

Epic Sciences is collaborating with Fulgent Genetics (FLGT) to deliver DefineMBC comprehensive profiling results for patients with metastatic breast cancer ((MBC)).The partnership…

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (NASDAQ: ADGI) announced th

FLGT earnings call for the period ending December 31, 2021.

FLGT earnings call for the period ending December 31, 2021.

Fullgent Genetics (FLGT) delivered earnings and revenue surprises of 25.56% and 31.01%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Shares of Fulgent Genetics (FLGT) are down 12% in after-hours trading despite quarterly results that beat on the top and bottom lines.

Fulgent Genetics (FLGT) announced a strategic investment in Spatial Genomics.FLGT is investing up to $40M to lead Spatial''s series A financing, which totals ~$56M

Fulgent Genetics press release (FLGT): Q4 Non-GAAP EPS of $3.48 beats by $0.81.Revenue of $251.7M beats by $60.6M.Shares -5%.Outlook Q1 2022:T otal Revenue of approximately…

TEMPLE CITY, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics,” “Fulgent,” or the “Company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced financial results for its fourth quarter and full year ended December 31, 2021. Fourth Quarter 2021 Results: Revenue of $251.7 million Billable tests delivered approximately 2.5 million Core Revenue grew 234%

Fullgent Genetics (FLGT) delivered earnings and revenue surprises of 25.56% and 31.01%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Fulgent Genetics, Inc. (FLGT) CEO Ming Hsieh on Q4 2021 Results - Earnings Call Transcript

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kodiak's Wet AMD Treatment KSI-301 Did Not Meet Primary Endpoint In Phase 2b/3 Study Kodiak Sciences